磷酸二酯酶4抑制剂治疗慢性阻塞性肺疾病的个性化选择  

The personalized choice of phosphodiesterase 4 inhibitor in patients with chronic obstructive pulmonary disease

作　　者：郑劲平[1] 

机构地区：[1]广州医科大学附属第一医院广州呼吸疾病研究所国家呼吸系统疾病临床医学研究中心呼吸疾病国家重点实验室,广州510120

出　　处：《中国实用内科杂志》2015年第5期386-388,共3页Chinese Journal of Practical Internal Medicine

基　　金：国家科技发展计划项目(2012BAI05B01;2013BAI09B09;2015BAI12B10)

摘　　要：罗氟司特是首个成功在欧美等地上市的口服治疗用于慢性阻塞性肺疾病(简称慢阻肺)的选择性磷酸二酯酶4抑制剂。体内外实验显示其能抑制多种炎症细胞,调节慢阻肺疾病相关的关键环节。循证医学研究证实,其能有效减少慢阻肺的急性加重、改善肺功能。罗氟司特耐受性一般良好,常见不良事件主要为胃肠道反应。由于气道和肺部炎症是慢阻肺的重要发病机制,在强调个体化治疗的今天,罗氟司特更适用于以慢支炎或合并慢支炎为主要临床表型的慢阻肺患者。对于轻症慢阻肺患者的有效性有待进一步探讨。Roflumilast is the selective phosphodiesterase 4 inhibitor available in the market of European Countries and United States for oral treatment of chronic obstructive disease（COPD）. In vivo and in vitro experimental studies showed that it can reduce the activities of multiple inflammatory cells and adjust the key mechanisms in the development of COPD. Evidence-based medicine has confirmed that roflumilast significantly decrease acute exacerbation of COPD and improve pulmonary function. It is well tolerated and the common adverse events are gastrointestinal reactions. For inflammations of the airway and the lung are the key mechanisms in the development of COPD, roflumilast might be more appropriate to be used in COPD patients with or complicated with chronic bronchitis as the main clinical phenotypes. It is recommended to further explore the effectiveness ofroflumilast in patients with mild COPD.

关 键 词：磷酸二酯酶4抑制剂 罗氟司特 慢性阻塞性肺疾病 个体化治疗 

分 类 号：R562[医药卫生—呼吸系统]